Revenue from operations stood at Rs 636.26 crore for the quarter under consideration, as against Rs 595.41 crore a year ago, it added.
“During the quarter the company has entered into a business transfer agreement with Mylan Pharmaceuticals Pvt Ltd to transfer certain primarily off-patented and generic established medicines business (Upjohn Business) as a going concern for a consideration of Rs 180.48 crore,” Pfizer Ltd said.
Completion of transaction is subject to fulfilment of certain conditions as set out in the agreement, it added.
The Upjohn business comprises six brands — Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin.
Revenue for the Upjohn business for the quarter ended September 2021 is Rs 21.1 crore, the filing said.
Shares of Pfizer Ltd closed at Rs 5,028.35 on BSE, down 1 per cent from its previous close.
